Basel Medical Group Ltd
corporate_fare Company Profile
Basel Medical Group Ltd (NASDAQ:BMGL) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 11 items for BMGL at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-23, rated 8/10. Across its 11 most recent items scored 7 or higher, the top rating is 9/10, with 8 rated 8 or above. Recent SEC coverage for BMGL spans F-1/A, F-1, 6-K, 20-F/A.
Recent high-impact activity:
- Basel Medical Prices 6M-Unit Offering at $1.33 with Zero-Cash Warrants
- Basel Medical Group Files to Sell Up to 6M Units with Warrants
- Basel Medical Files F-1 for Up to 6M Units with Zero-Cash Warrants
- Basel Medical Group Faces Securities Class Action Alongside Over 30 Companies
- Basel Medical Group Reports Profit Turnaround Amidst Going Concern Doubts and Significant Cash Burn
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 159,585 shares in BMGL as of the September 15, 2026 settlement, a 1917.0% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On October 2, 2026, 72.5% of BMGL volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for BMGL, detected from its recent SEC filings · based on capital-structure filings through 2026-09-23.
Offering Priced at $1.33 Per Unit · Zero-Cash Warrant Exercise Adds Dilution
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
BMGL files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.